Our laboratory is interested in the molecular and cellular mechanisms of protection after traumatic brain injury (TBI), ischemic stress and age-associated neurodegenerative diseases. A major focus of our work is to understand the role of astrocytes in these disease processes, which are known to play key roles in supporting and protecting neurons. We were the first lab to demonstrate the increased astrocyte mitochondrial ATP production significantly decreased brain injuries after stroke and TBI/CTE. We are currently investigating the impact of a new therapeutic, based on this work, to slow the onset and severity of Alzheimer’s disease. Astrocyte Pharmaceuticals is a privately held pharmaceutical company, co-founded by me, developing and commercializing therapeutic approaches associated with our research. The first neuroprotective molecule AST-004 has successfully advanced through phase 1 clinical trials in humans with no significant adverse effects. Phase 2 efficacy trials in humans are planned for early 2024.

Friday, November 10, 2023
Virtually from 9:00 AM - 10:00 AM

For information on participating in the current monthly seminar, please head to https://utsa.edu/crts/strech/ or scan the QR code below

James D. Lechleiter, PhD
Professor, Cell Systems and Anatomy
Director, Optical Imaging Core Facility
Co-Director, Center for Precision Medicine
Co-Director, SABER, IRACDA K12 Program
UT Health San Antonio